ZYNLONTA Added to NCCN Guidelines

I am pleased to inform you that the NCCN Guidelines^® have been updated to include loncastuximab tesirine-lpyl (ZYNLONTA™, ADC Therapeutics) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

NCCN Guidelines recommend loncastuximab tesirine-lpyl (ZYNLONTA™) as a third-line and subsequent therapy option for patients with relapsed or refractory DLBCL who have received ≥2 systemic therapies.

For more information, visit adctherapeutics.com

INDICATION AND USAGE

ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

See full prescribing information.